QurientQurient

팝업레이어 알림

팝업레이어 알림이 없습니다.

최신글

Innovation for
Unmet
Medical
Needs

Global Leader
of Network
R&D

Clinical & non-clinical
pipeline with
Global
standard

  • Notice

      2024-04-19
      신주발행공고
      2024-03-28
      주식회사 큐리언트 제16기 결산공고
      2024-03-20
      주식회사 큐리언트 제16기 연결 및 별도 감사보고서
      2024-03-20
      주식회사 큐리언트 제16기 사업보고서
      2024-03-04
      큐리언트 기업설명회 IR 자료 공지
  • Press Release

      2024-06-14
      큐리언트 면역항암제 ‘아드릭세티닙’,희귀 혈액암 임상 IND 승인
      2024-05-27
      큐리언트, Q901 ASCO 초록 공개…안전성·약물반응 검증
      2024-05-23
      큐리언트, 우선심사권 걸린 '텔라세벡' 허가 임상 본격화
      2024-05-22
      큐리언트, 美 NCI와 연구 계약 "머크와 BMS도 거쳐간 블록버스터 등용문"
      2024-05-21
      큐리언트 "美 정부 지원 받아 소세포성폐암 임상, CDK7 저해 기술력 인정받았다"
  • Company

    Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model.See More

  • Business philosophy

    Innovation for unmet medical needs

    Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders. See More

  • Pipeline

    Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.See More

  • IR/PR

    Dear Qurient shareholders

    Qurient would like to share brief updates on current progress made on its portfolio programs. See More

information for download file